Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) shares saw strong trading volume on Monday after UBS Group raised their price target on the stock from $21.00 to $22.00. UBS Group currently has a buy rating on the stock. 17,251 shares were traded during trading, an increase of 41% from the previous session’s volume of 12,207 shares.The stock last traded at $18.60 and had previously closed at $18.24.
Separately, William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
Read Our Latest Stock Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 1.7 %
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
See Also
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Buy P&G Now, Before It Sets A New All-Time High
- Sizing Up a New Opportunity for NVIDIA Investors
- Stock Analyst Ratings and Canadian Analyst Ratings
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- The Risks of Owning Bonds
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
